Authors
Latest:
Promising New Regimens for Treating Acute Myeloid LeukemiaAlice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.
Latest:
The Ideal Patient for Biomarker Testing in Anal CarcinomaCathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.
Latest:
Identifying Post CAR-T Issues in Community Oncology PatientsMazyar Shadman, MD, MPH, explains how community oncologists can care for their patient after they have been treated with chimeric antigen receptor T cells.
Latest:
AI-Derived Biomarker Predicts Benefit of Long-Term ADT in Prostate CancerAndrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.
Latest:
Importance of NAPOLI 3 in Pancreatic Cancer for Community OncologistsZev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.
Latest:
Hillmen Analyzes Current and Upcoming Trials of BTK InhibitorsDuring a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.
Latest:
Recommendations for Treating Patients With TP53-Mutated AML or MDSMelhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.
Latest:
Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid LeukemiaAllogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.
Latest:
Improved Communication Needed for Patients Living with Renal Cell CarcinomaA lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.
Latest:
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHLScott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.
Latest:
20 Years of Trials, Hope and Progress for Patients with Pancreatic AdenocarcinomaIn a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.
Latest:
Future Treatment Landscape for RRMMMultiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.
Latest:
Tackling Cancer Care in the Face of Climate ChangeLeticia Nogueira, PhD, MPH, discusses how healthcare professionals and patients can come together facing the threats of climate change on cancer care.
Latest:
Behind the FDA Approval of Fruquintinib for Previously Treated mCRCIn season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
Latest:
Integrating Personalized Medicine: Advice for Medical OncologistsTracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.
Latest:
TIL Quantity Greatly Impacts Survival in Metastatic Breast CancerIn an interview with Targeted Oncology, Daniel G. Stover, MD, highlighted the objective to enhance delivery of endocrine therapy plus CDK4/6 inhibitors to patients with hormone receptor-positive, HER2-negative breast cancer by utilizing biomarker assessments as a guide to interchange or cease treatment at the most favorable time.
Latest:
Exploring the Updated Efficacy of the CheckMate 214 Trial in RCCUlka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Latest:
Pano/GemBuMel is Safe and Effective in High-Risk or Relapsed/Refractory MyelomaYago Nieto, MD, PhD, discusses the findings from a phase 2 trial evaluating treatment with panobinostat, gemcitabine, busulfan, and melphalan for high-risk or relapsed/refractory myeloma.
Latest:
Administering CAR T-Cell Therapy in the Community SettingPeter A. McSweeney, MD, discusses the challenges that come with administering chimeric antigen receptor T-cell therapy. He also explains how CAR T cells entering the second-line may change the ways community practices choose treatments for their patients.
Latest:
Andorsky on the Shifting Treatment Landscape of BTKi Use in CLL/SLLDavid J. Andorsky, MD, discusses findings from a retrospective study of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma from ASH 2023.
Latest:
Moving Forward With Ibrutinib Plus Venetoclax in MCLMatthew Matasar, MD, discusses the next steps for the development of ibrutinib given in combination with venetoclax for patients with mantle cell lymphoma, and potential challenges with using the combination.
Latest:
World Neuroendocrine Cancer Awareness Day: Therapeutic Options for Well-differentiated NETsAjaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors.
Latest:
Exploring the Role of Gut Microbiome in Cancer TherapyThe normal gut microbiota metabolizes nutrients and drugs, maintains the gut mucosal barrier integrity, protects against pathogens, and trains and develops the immune system. The gut microbiome has been implicated in many human pathologies.
Latest:
Navigating Treatment Choices in Urothelial CancerGuru P. Sonpavde, MD, provides insights on the phase 3 CheckMate 901 trial and explains what a community oncologist should know about the use of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma based on this study.
Latest:
Sequencing Osimertinib in Patients With EGFR-Mutated NSCLCAparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.
Latest:
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaMahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Latest:
Glofitamab Leads to Responses in Relapsed/Refractory LBCLCyrus M. Khan, MD, discusses the eligibility criteria of a phase 1/2 study evaluating glofitamab for the treatment of patients with large B-cell lymphoma, and provides data from the expansion cohorts of the trial.
